JACC. Case reports · 2025
Relief of Refractory Angina With Vericiguat.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Vidanage Ashen L, Dong Yugang, Liu Jun, Liu Chen, Zhao Jing Jing
Аннотация
BACKGROUND: Refractory angina represents a challenging clinical symptom, with limited therapeutic options beyond conventional antianginal therapy and revascularization.
CASE SUMMARY: A 43-year-old man with a history of hypertension, diabetes mellitus, and coronary atherosclerotic heart disease presented with persistent angina pectoris, classified as Canadian Cardiovascular Society class IV, despite being on optimized antianginal therapy including calcium-channel blockers, nitrates, and other adjunctive medications. His Seattle Angina Questionnaire score was 12.61. Introduction of vericiguat 10 mg daily resulted in marked symptom improvement, with Seattle Angina Questionnaire score increasing to 57.35 and angina classification improving to class II.
DISCUSSION: This represents to our knowledge the first documented use of vericiguat for refractory angina. Vericiguat stimulates soluble guanylate cyclase and enhances cyclic GMP production, improving endothelial dysfunction and impaired vasodilation; this may be the mechanism by which it relieves refractory angina.
TAKE-HOME MESSAGES: Vericiguat may offer therapeutic benefit in refractory angina patients unresponsive to conventional therapy. Further investigation is warranted.
CASE SUMMARY: A 43-year-old man with a history of hypertension, diabetes mellitus, and coronary atherosclerotic heart disease presented with persistent angina pectoris, classified as Canadian Cardiovascular Society class IV, despite being on optimized antianginal therapy including calcium-channel blockers, nitrates, and other adjunctive medications. His Seattle Angina Questionnaire score was 12.61. Introduction of vericiguat 10 mg daily resulted in marked symptom improvement, with Seattle Angina Questionnaire score increasing to 57.35 and angina classification improving to class II.
DISCUSSION: This represents to our knowledge the first documented use of vericiguat for refractory angina. Vericiguat stimulates soluble guanylate cyclase and enhances cyclic GMP production, improving endothelial dysfunction and impaired vasodilation; this may be the mechanism by which it relieves refractory angina.
TAKE-HOME MESSAGES: Vericiguat may offer therapeutic benefit in refractory angina patients unresponsive to conventional therapy. Further investigation is warranted.